SCI Cancer Clinical Trials Office Blog

News & Updates from the SCI-CCTO
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
  • Cancer Clinical Trials Office
  • Stanford Cancer Institute

Mogamulizumab Receives FDA Approval

August 9, 2018 - SCI Communications

Mogamulizumab (sponsor: Kyowa-Kirin) was approved this week for use in Cutaneous T-Cell Lymphoma (CTCL) for patients who received 1 prior line of therapy. Stanford’s multi-disciplinary Cutaneous Lymphoma team (PI: Dr. Youn Kim) as the lead site for this study had a successful FDA inspection in December 2017, paving the way for its accelerated approval.

Hats off to the hard work of all the members of this team.

Blog Submissions

If you have an announcement for the blog, please complete the Comms Request Form.

Reminder: Please have your blog post submitted to us by noon on Wednesday in order to have your post featured in the weekly email digest on Friday morning.

Archives

Categories

  • Announcements
  • Clinical Trials
  • Coordinator Corner
  • Educational Training
  • Events
  • Intake Process
  • IRB Updates
  • kudos
  • OnCore
  • Quality Corner
  • Regulatory Updates
  • Remote Monitoring
  • SCI Messages
  • Scientific Review Committee (SRC)
  • SOP/Guideline Updates
  • Staff Updates
  • Uncategorized
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube